As disquiet grows, a new opioid aims to check addiction crisis

1 June 2017

A new agreement between Japan’s Daiichi Sankyo (TYO: 4568) and the New Jersey-based biotech startup Inspirion Delivery Sciences will see the commercialization of newly-approved painkiller RoxyBond (oxycodone hydrochloride) in the USA.

The drug, the first immediate-release opioid analgesic labelled as having abuse-deterrent properties, enters the market at an important time for the analgesics industry, amid a rising tide of addiction and a gathering storm of sentiment against prescription opioids.

RoxyBond is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK